Theriva Biologics, Inc. Common Stock
Key Metrics
Market Snapshot
About
Theriva Biologics, Inc. Common Stock (TOVX) is a clinical-stage company headquartered in Rockville, Maryland, that develops therapeutics for cancer and related diseases in areas of high unmet need in the United States. The company is best known for its work on an oncolytic virus aimed at hard-to-treat solid tumors, along with a pipeline of treatments targeting gastrointestinal and related conditions.
The company's lead product candidate is VCN-01, also identified as zabilugene almadenorepvec, a clinical-stage oncolytic human adenovirus. It is being studied in Phase 1 trials and in the Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. Theriva is also developing VCN-11 for solid tumors. Beyond its cancer programs, the company is advancing SYN-004, also called ribaxamase, an oral capsule therapy in Phase 1b/2a trials intended to help prevent acute graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplant, and SYN-020, an oral form of the enzyme intestinal alkaline phosphatase for several gastrointestinal and metabolic uses.
The company's pipeline also includes SYN-006, aimed at preventing graft-versus-host disease, Clostridioides difficile infection, and microbiome damage in patients on carbapenem antibiotics, and SYN-007, designed to prevent antibiotic-associated diarrhea with oral beta-lactam antibiotics. Theriva has a license agreement with Rasayana Therapeutics covering products that include SYN-020 and a clinical trial agreement with Washington University School of Medicine in St. Louis for a SYN-004 study. As a clinical-stage developer, TOVX is focused on advancing these candidates through trials rather than selling approved products.